Opinion: The Public Is Unified On Lowering Drug Prices. Why Are Leaders Settling For Less?
PhRMA regards drug price negotiation for Medicare as an existential threat to its business — potentially costing billions.
PhRMA regards drug price negotiation for Medicare as an existential threat to its business — potentially costing billions.
More than 100 separate bills regulating pharmacy benefit managers that serve as conduits for drug manufacturers have been introduced in 42 states, including Oregon, this year,
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
Residents will have to wait to see whether the Oregon Legislature’s increased spending and regulation of the health care industry will yield results.
Starting this month, most people with private insurance will no longer have to decide whether they can afford to protect themselves against HIV.
Health insurance companies will have to give their customers estimated out-of-pocket costs for prescription drugs and disclose to the public the negotiated prices they pay for drugs.
Advocates say a new rule will make it harder for patients with conditions such as cancer and multiple sclerosis who rely on very expensive drugs to afford them.
The drug company trade group PhRMA has filed a legal challenge to a pair of Oregon laws designed to curb prescription prices.
The Pharmaceutical Research and Manufacturers of America filed suit in Eugene against two bills that passed the Oregon Legislature with bipartisan support.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
SALEM – For six years, Oregon pharmacies have been lobbying the state Legislature to rein in fees imposed on them by pharmacy benefit managers, the third-party intermediaries that negotiate prices with drug manufacturers and prescription drug claims with insurers.
Medicare enrollees, who have watched their out-of-pocket spending on prescription drugs climb in recent years, might be in for a break.
Access to powerful new cholesterol-lowering drugs is so tightly controlled and patients’ out-of-pocket costs are so high that fewer than a third of people whose doctors prescribe the drugs get them, a new study found.